Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study
Open Access
- 12 April 2021
- journal article
- research article
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 64 (1), 1-34
- https://doi.org/10.1192/j.eurpsy.2021.23
Abstract
Background Poor adherence to antipsychotic drugs is a major problem in schizophrenia management and one of the most important risk factors for relapse and hospitalization. To date, there is little evidence on persistence predictors with long-acting injectable antipsychotics, especially with aripiprazole once-monthly (AOM). This study (NCT03130478) aimed to describe the impact of demographic and clinical characteristics on persistence with AOM treatment in real-world setting. Methods This was an observational, retrospective, non-interventional study that included adult patients with schizophrenia who were initiated on AOM during a schizophrenia-related hospitalization. Data were retrospectively collected from patients' medical records. The primary variable was persistence with AOM, measured as the number of days from AOM initiation up to all-cause AOM discontinuation during the first six months after treatment index. Results 140 patients were enrolled and 91 fulfilled the selection criteria. Six months after AOM initiation, 65 (71.4%) patients were still receiving AOM treatment, whereas 26 (28.6%) were not. The mean (standard deviation) time to AOM treatment discontinuation in the first six months was 138.1 (6.8) days, with most of the patients discontinuing at the first 28 days. The risk of AOM discontinuation in the first six months increases 1.05-fold annually since schizophrenia diagnosis (p=0.003); moreover, this risk increases 2.86-fold in patients with concomitant schizophrenia medication at AOM initiation compared to patients without concomitant schizophrenia treatments (p=0.02). Conclusions Main factors predicting persistence with AOM treatment at six months in clinical practice are fewer years since schizophrenia diagnosis and not receiving concomitant schizophrenia treatments at AOM initiation.Keywords
This publication has 64 references indexed in Scilit:
- Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaPatient Preference and Adherence, 2013
- Relapse Duration, Treatment Intensity, and Brain Tissue Loss in Schizophrenia: A Prospective Longitudinal MRI StudyAmerican Journal of Psychiatry, 2013
- Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophreniaJournal of Medical Economics, 2013
- Efficacy and safety of second-generation long-acting injections in schizophreniaInternational Clinical Psychopharmacology, 2013
- The nature of relapse in schizophreniaBMC Psychiatry, 2013
- Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature reviewTherapeutic Advances in Psychopharmacology, 2013
- Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and BelgiumAnnals of General Psychiatry, 2011
- Partial Adherence to Antipsychotic Medication Impacts the Course of Illness in Patients With SchizophreniaThe Primary Care Companion For CNS Disorders, 2009
- The Expert Consensus Guideline SeriesBritish Journal of Psychology, 2009
- Psychobiologic correlates of treatment response in schizophreniaNeuropsychopharmacology, 1996